CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 479 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,978,711 | -34.4% | 36,636 | -17.2% | 0.38% | -34.5% |
Q1 2024 | $3,015,808 | +7.7% | 44,246 | -1.1% | 0.59% | +1.6% |
Q4 2023 | $2,800,599 | +33.7% | 44,738 | -3.1% | 0.58% | +18.2% |
Q3 2023 | $2,094,704 | +56.4% | 46,149 | +40.1% | 0.49% | +46.3% |
Q2 2023 | $1,339,052 | 0.0% | 32,941 | 0.0% | 0.34% | 0.0% |
Q1 2023 | $1,339,052 | 0.0% | 32,941 | 0.0% | 0.34% | 0.0% |
Q4 2022 | $1,339,052 | -32.0% | 32,941 | +9.4% | 0.34% | -35.8% |
Q3 2022 | $1,968,000 | +20.4% | 30,118 | +11.9% | 0.52% | +16.8% |
Q2 2022 | $1,635,000 | +11.7% | 26,905 | +15.4% | 0.45% | +40.6% |
Q1 2022 | $1,464,000 | -14.0% | 23,324 | +3.8% | 0.32% | -15.4% |
Q4 2021 | $1,703,000 | -38.9% | 22,472 | -9.7% | 0.38% | -43.1% |
Q3 2021 | $2,786,000 | -32.4% | 24,891 | -2.2% | 0.66% | -31.7% |
Q2 2021 | $4,122,000 | +305.7% | 25,460 | +205.2% | 0.97% | +273.7% |
Q1 2021 | $1,016,000 | +28.1% | 8,342 | +61.1% | 0.26% | +29.5% |
Q4 2020 | $793,000 | – | 5,178 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |